secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001558370-25-011145
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Q2 2025 net loss of $22.1M; positive pemvidutide MASH data reinforces differentiation
--------------------------------------------------------------------------------

- Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.
- Pemvidutide achieved up to 59.1% MASH resolution without worsening fibrosis, up to 34.5% fibrosis improvement, and up to 6.2% weight loss at 24 weeks.
- New cT1 imaging data shows mean decreases of 145-148 ms (p<0.001), potentially class-leading in MASH trials.
- End-of-Phase 2 FDA meeting targeted for Q4 2025; full 48-week data expected Q4.
- Jerry Durso appointed Chairman; Mitchel Sayare remains director as part of board succession.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/0001558370-25-011145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/alt-20250812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer